



MEDPLUS[®] ANNOUNCES RECORD CHARTMAXX ORDERS AND 49% INCREASE IN QUARTERLY REVENUES

Cincinnati, September 6, 2000 – MedPlus, Inc. (NASDAQ: MEDP) today announced second quarter and six-month results of operations. Highlights for the three-month period ended July 31, 2000 were as follows:

- Revenues increased 49.3% over the comparable quarter of fiscal 2000.
- The contract value of orders in the second quarter for the ChartMaxx[™] Private Health Record System was the highest quarterly total in company history.
- Quest Diagnostics Incorporated (NYSE: DGX) invested \$10,000,000 in MedPlus common stock to acquire an 18.4% interest in the voting stock of the Company.
- The Company retired all indebtedness and is now debt-free.
- The Company completed its first international implementation of ChartMaxx at St. Eustache Medical Center in Montreal, Quebec.

“The second quarter reflected a dramatic improvement in sales performance,” said Richard A. Mahoney, Chairman and Chief Executive Officer of MedPlus. “ChartMaxx contracts executed during this quarter approximated the value of the total orders received during the past two fiscal years. In addition, the individual contract values are significantly higher than in previous years. While certain orders received this year have not been recognized as revenue in accordance with our revenue recognition policies, we have added significant amounts to our revenue backlog.”

Mahoney continued, “The investment in our Company by Quest Diagnostics and the associated co-marketing agreement are very important developments. We have retired all outstanding indebtedness, added a significant amount of working capital and equity and dramatically improved our overall financial condition. We have spent a significant amount of time in developing training and marketing programs with the Quest Diagnostics sales and marketing organizations and believe this will provide our Company with exceptional future revenue opportunities.”

Mahoney concluded, “The first six months of operations reflect substantial expenditures made to further our E-health initiative. These expenditures include significant increases in our development, project management and integration services personnel. We are also aggressively pursuing integration relationships with companies involved with on-line transcription, scripting and training in an effort to enhance the value of our solutions to the physician community. We believe these investments and business relationships will enable our Company to become a leading provider of patient-centric, HIPAA compliant private health record systems in the United States.”

MedPlus is a leading provider of Internet-enabled clinical information management systems that enable health care organizations to implement electronic patient record systems. The Company’s ChartMaxx and E.Maxx[™] systems can interface with any installed legacy system to provide better care for patients, greater productivity for physicians and cost savings for hospitals. The Company has over 30 electronic patient record sites and over 100 imaging sites at hospitals in the United States and Canada. For more information, visit the Company’s web site at www.medplus.com.

MedPlus notes that many of the statements made herein are forward-looking statements. As such, factors may occur which could cause actual events to differ materially from those anticipated in these statements. For example, although the Company is aggressively pursuing integration relationships with companies involved with on-line transcription, scripting and training, none of these relationships has been finalized and there can be no guarantee that the parties negotiating such relationships will be able to complete such negotiations in the near future.

Contacts:
Philip S. Present, President and Chief Operating Officer
(513) 583-0500
ppresent@medplus.com

Melissa Lemmon, Director of Marketing
(513) 583-0500
mlemmon@medplus.com

Consolidated Statements of Operations
(unaudited)

	Three Months Ended July 31, 2000	Three Months Ended July 31, 1999	Six Months Ended July 31, 2000	Six Months Ended July 31, 1999
Revenues:				
Systems sales	\$ 1,468,600	798,900	2,844,800	3,681,100
Support and consulting revenues	1,025,000	871,000	2,549,200	1,807,500
Total revenues	<u>2,493,600</u>	<u>1,669,900</u>	<u>5,394,000</u>	<u>5,488,600</u>
Cost of revenues:				
Systems sales	1,024,800	645,900	1,678,700	2,063,000
Support and consulting revenues	998,300	797,800	1,902,100	1,696,600
Total cost of revenues	<u>2,023,100</u>	<u>1,443,700</u>	<u>3,580,800</u>	<u>3,759,600</u>
Gross profit	470,500	226,200	1,813,200	1,729,000
Operating expenses:				
Sales and marketing	746,000	563,400	1,585,200	1,427,100
Research and development	733,100	385,200	1,244,000	671,400
General and administrative	1,013,300	906,600	1,784,100	1,790,200
Total operating expenses	<u>2,492,400</u>	<u>1,855,200</u>	<u>4,613,300</u>	<u>3,888,700</u>
Operating loss	(2,021,900)	(1,629,000)	(2,800,100)	(2,159,700)
Other income (expense):				
Interest expense	(70,500)	(141,400)	(213,600)	(208,500)
Other income (expense), net	(110,600)	40,800	(63,400)	57,400
Synergis management and offering costs	--	--	--	(179,700)
Total other income (expense), net	<u>(181,100)</u>	<u>(100,600)</u>	<u>(277,000)</u>	<u>(330,800)</u>
Loss from continuing operations before income tax benefit	(2,203,000)	(1,729,600)	(3,077,100)	(2,490,500)
Income tax benefit	--	--	--	--
Loss from continuing operations (a)	<u>(2,203,000)</u>	<u>(1,729,600)</u>	<u>(3,077,100)</u>	<u>(2,490,500)</u>
Loss from discontinued operations (b)	--	(329,800)	--	(648,700)
Net loss	(2,203,000)	(2,059,400)	(3,077,100)	(3,139,200)
Conversion discount on preferred stock	--	(346,300)	--	(346,300)
Preferred stock dividend requirements	(82,000)	(82,000)	(82,000)	(82,000)
Loss attributable to common shareholders	<u>\$ (2,285,000)</u>	<u>(2,487,700)</u>	<u>(3,159,100)</u>	<u>(3,567,500)</u>
Net loss per common share – basic and diluted:				
Continuing operations	\$ (0.35)	(0.36)	(0.50)	(0.48)
Discontinued operations	--	(0.05)	--	(0.11)
Net loss per common share	<u>\$ (0.35)</u>	<u>(0.41)</u>	<u>(0.50)</u>	<u>(0.59)</u>
Weighted average number of shares of common stock outstanding	<u>6,503,226</u>	<u>6,041,269</u>	<u>6,356,684</u>	<u>6,038,776</u>

Footnotes to Consolidated Statements of Operations

- (a) Results from continuing operations for both periods presented include the results of the Company's two segments: Health care Solutions (including ChartMaxx Enterprise-wide Electronic Patient Record System, E.Maxx Enterprise-wide Electronic Patient Record System, OptiMaxx Archival System and FutureCORE, Inc.), and Workflow and Document Management (through its wholly owned subsidiary Universal Document Management Systems, Inc.)
- (b) Discontinued Operations includes the results of operations of the Company's majority-owned subsidiary, DiaLogos, which was divested in March 2000.